The recent share price pullback of ResMed (RMD) has led experts to reassess its position. Market news indicates the company targets growth in North America with its new Greenwood distribution hub. 2Xideas AG and First Trust Advisors LP have substantially increased their holdings following the pullback.
Certain investors such as Blair William & Co. and Victory Capital Management Inc. have sold off their shares. Meanwhile, the CEO and CFO of ResMed have offloaded shares after option exercise and Rule 10b5-1 trade respectively. Notably, ResMed's earnings have displayed positive growth and the firm has started strong for the fiscal year 2026.
A New Greenwood distribution expansion is also expected to impact ResMed's performance. Despite some negative market reactions, such as a share price decline and downgrade to 'Hold', many analysts still show confidence in the stock with an average recommendation of 'Moderate Buy'.
Resmed RMD News Analytics from Tue, 29 Jul 2025 07:00:00 GMT to Sat, 14 Mar 2026 13:09:28 GMT - Rating 3 - Innovation 4 - Information 7 - Rumor -2
